Sequential treatment with immunotherapy and checkpoint inhibitors prolongs anti-tumor activity
Advanced melanoma is one of the deadliest types of cancer, with a 5-year survival rate of only 27% for patients with distant metastases. Recent advances in targeted therapies and immunotherapies have greatly improved patient ...
Mar 2, 2021
0
12